Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.
No abstract available

MeSH terms

  • Cell- and Tissue-Based Therapy
  • Hematologic Neoplasms* / pathology
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Lymphoma, B-Cell* / therapy
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen